Reference Pricing for Healthcare Services

References

• Adida E (2021) Outcome-based pricing for new pharmaceuticals via rebates. Management Sci. 67(2):892–913.Link, Google Scholar
• Adida E, Mamani H, Nassiri S (2017) Bundled payment vs. fee-for-service: Impact of payment scheme on performance. Management Sci. 63(5):1606–1624.Link, Google Scholar
• Aksoy-Pierson M, Allon G, Federgruen A (2013) Price competition under mixed multinomial logit demand functions. Management Sci. 59(8):1817–1835.Link, Google Scholar
• Allon G, Federgruen A (2009) Competition in service industries with segmented markets. Management Sci. 55(4):619–634.Link, Google Scholar
• Anderson SP, De Palma A, Thisse J-F (1992) Discrete Choice Theory of Product Differentiation (MIT Press, Cambridge, MA).Crossref, Google Scholar
• Andritsos D, Tang CS (2018) Incentive programs for reducing readmissions when patient care is co-produced. Production Oper. Management 27(6):999–1020.Crossref, Google Scholar
• Antoñanzas F, Juárez-Castelló CA, Rodríguez-Ibeas R (2017) Endogenous vs. exogenous generic reference pricing for pharmaceuticals. Internat. J. Health Econom. Management 17(4):413–432.Crossref, Google Scholar
• Bardey D, Bommier A, Jullien B (2010) Retail price regulation and innovation: Reference pricing in the pharmaceutical industry. J. Health Econom. 29(2):303–316.Crossref, Google Scholar
• Baron DP, Myerson RB (1982) Regulating a monopolist with unknown costs. Econometrica 50(4):911–930.Crossref, Google Scholar
• Barros PP (2011) The simple economics of risk-sharing agreements between the NHS and the pharmaceutical industry. Health Econom. 20(4):461–470.Crossref, Google Scholar
• Binmore K, Rubinstein A, Wolinsky A (1986) The Nash bargaining solution in economic modelling. RAND J. Econom. 17(2):176–188.Crossref, Google Scholar
• Brekke KR, Canta C, Straume OR (2016) Reference pricing with endogenous generic entry. J. Health Econom. 50:312–329.Crossref, Google Scholar
• Brekke KR, Königbauer I, Straume OR (2007) Reference pricing of pharmaceuticals. J. Health Econom. 26(3):613–642.Crossref, Google Scholar
• Brown TT, Robinson JC (2016) Reference pricing with endogenous or exogenous payment limits: Impacts on insurer and consumer spending. Health Econom. 25(6):740–749.Crossref, Google Scholar
• Centers for Medicare & Medicaid Services (2013) Centers for Medicare & Medicaid Services – Hospital Compare. Accessed February 7, 2019, https://www.medicare.gov/hospitalcompare/search.html.Google Scholar
• Centers for Medicare & Medicaid Services (2018) Fiscal Year (FY) 2019 Medicare Hospital Inpatient Prospective Payment System (IPPS) and Long-Term Acute Care Hospital (LTCH) Prospective Payment System Final Rule (CMS-1694-F). Accessed February 7, 2019, https://tinyurl.com/ybfvtcnf.Google Scholar
• Cooper Z, Craig S, Gaynor M, Van Reenen J (2019) The price ain’t right? Hospital prices and health spending on the privately insured. Quart. J. Econom. 134(1):51–107.Google Scholar
• Danzon PM, Ketcham JD (2004) Reference pricing of pharmaceuticals for Medicare: Evidence from Germany, The Netherlands and New Zealand. Frontiers Health Policy Res. 7(2004):1–54.Google Scholar
• Denoyel V, Alfandari L, Thiele A (2017) Optimizing healthcare network design under reference pricing and parameter uncertainty. Eur. J. Oper. Res. 263(3):996–1006.Crossref, Google Scholar
• Dranove D (1996) Measuring costs. Sloan FA, ed. Valuing Healthcare: Costs, Benefits, and Effectiveness of Pharmaceuticals and Other Medical Technologies (Cambridge University Press, Cambridge, UK), 61–76.Google Scholar
• Eijkenaar F, Emmert M, Scheppach M, Schöffski O (2013) Effects of pay for performance in healthcare: A systematic review of systematic reviews. Health Policy 110(2-3):115–130.Crossref, Google Scholar
• Fronstin P, Roebuck MC (2014) Reference pricing for healthcare services: A new twist on the defined contribution concept in employment-based health benefits. EBRI Issue Brief No. 398, Employee Benefit Research Institute, Washington, DC.Google Scholar
• Ghislandi S (2011) Competition and the reference pricing scheme for pharmaceuticals. J. Health Econom. 30(6):1137–1149.Crossref, Google Scholar
• Guo P, Tang CS, Wang Y, Zhao M (2019) The impact of reimbursement policy on social welfare, revisit rate, and waiting time in a public healthcare system: Fee-for-service vs. bundled payment. Manufacturing Service Oper. Management 21(1):154–170.Link, Google Scholar
• Gupta D, Mehrotra M (2015) Bundled payments for healthcare services: Proposer selection and information sharing. Oper. Res. 63(4):772–788.Link, Google Scholar
• Hayashi F (2011) Econometrics (Princeton University Press, Princeton, NJ).Google Scholar
• Jain DC, Vilcassim NJ, Chintagunta PK (1994) A random-coefficients logit brand-choice model applied to panel data. J. Bus. Econom. Statist. 12(3):317–328.Crossref, Google Scholar
• Kaiser U, Mendez SJ, Rønde T, Ullrich H (2014) Regulation of pharmaceutical prices: Evidence from a reference price reform in Denmark. J. Health Econom. 36:174–187.Crossref, Google Scholar
• Kouvelis P, Xiao Y, Yang N (2015) PBM competition in pharmaceutical supply chain: Formulary design and drug pricing. Manufacturing Service Oper. Management 17(4):511–526.Link, Google Scholar
• Lechner AE, Gourevitch R, Ginsburg PB (2013) The potential of reference pricing to generate healthcare savings: Lessons from a California pioneer. Center for Studying Health System Change Research Brief No. 30, National Institute for Health Care Reform, Washington, DC.Google Scholar
• López-Casasnovas G, Puig-Junoy J (2000) Review of the literature on reference pricing. Health Policy 54(2):87–123.Crossref, Google Scholar
• Ma CA, Mak HY (2015) Information disclosure and the equivalence of prospective payment and cost reimbursement. J. Econom. Behav. Organ. 117:439–452.Crossref, Google Scholar
• Mahjoub R, Ødegaard F, Zaric GS (2018) Evaluation of a pharmaceutical risk-sharing agreement when patients are screened for the probability of success. Health Econom. 27(1):e15–e25.Crossref, Google Scholar
• Mak HY (2018) Managing imperfect competition by pay for performance and reference pricing. J. Health Econom. 57:131–146.Crossref, Google Scholar
• NBCH (2012) Price transparency: Now more than ever. NBCH Action Brief, National Business Coalition of Health Action, Washington, DC.Google Scholar
• Newhouse JP, Garber AM, Graham RP, McCoy MA, Mancher M, Kibria A (2013) Variation in Healthcare Spending: Target Decision Making, Not Geography (National Academies Press, Washington, DC).Google Scholar
• Newman D, Parente ST, Barrette E, Kennedy K (2016) Prices for common medical services vary substantially among the commercially insured. Health Affairs 35(5):923–927.Crossref, Google Scholar
• Rémuzat C, Urbinati D, Mzoughi O, El Hammi E, Belgaied W, Toumi M (2015) Overview of external reference pricing systems in Europe. J. Market Access Health Policy 3(1):27675.Crossref, Google Scholar
• Robinson JC (2010) Applying value-based insurance design to high-cost health services. Health Affairs 29(11):2009–2016.Crossref, Google Scholar
• Robinson JC (2016) Reference pricing in health insurance. Accessed February 7, 2019, https://bcht.berkeley.edu/sites/default/files/utah_reference_pricing_082916.pdf.Google Scholar
• Robinson JC, Brown TT (2013) Increases in consumer cost sharing redirect patient volumes and reduce hospital prices for orthopedic surgery. Health Affairs 32(8):1392–1397.Crossref, Google Scholar
• Robinson JC, McPherson K (2012) Payers test reference pricing and centers of excellence to steer patients to low-price and high-quality providers. Health Affairs 31(9):2028–2036.Crossref, Google Scholar
• Robinson JC, Brown TT, Whaley C (2015) Reference-based benefit design changes consumers’ choices and employers’ payments for ambulatory surgery. Health Affairs 34(3):415–422.Crossref, Google Scholar
• Robinson JC, Brown TT, Whaley C (2016) Association of reference pricing for diagnostic laboratory testing with changes in patient choices, prices, and total spending for diagnostic tests. JAMA Internal Medicine 176(9):1353–1359.Crossref, Google Scholar
• Robinson JC, Brown TT, Whaley C (2017) Reference pricing changes the ‘choice architecture’ of healthcare for consumers. Health Affairs 36(3):524–530.Crossref, Google Scholar
• Rosenthal E (2013) The $2.7 trillion medical bill. New York Times (June 1), https://www.nytimes.com/2013/06/02/health/colonoscopies-explain-why-us-leads-the-world-in-health-expenditures.html.Google Scholar
• Train K (2003) Discrete Choice Methods with Simulation (Cambridge University Press, Cambridge, UK).Crossref, Google Scholar
• Truong V-A (2014) Optimal selection of medical formularies. J. Revenue Pricing Management 13(2):113–132.Crossref, Google Scholar
• Whaley C, Brown T, Robinson J (2019) Consumer responses to price transparency alone vs. price transparency combined with reference pricing. Amer. J. Health Econom. 5(2):227–249.Crossref, Google Scholar
• White C, Eguchi M (2014) Reference pricing: A small piece of the healthcare price and quality puzzle. National Institute for Healthcare Reform Research Brief No. 18, National Institute for Health Care Reform, Washington, DC.Google Scholar
• Zuvekas SH, Cohen JW (2016) Fee-for-service, while much maligned, remains the dominant payment method for physician visits. Health Affairs 35(3):411–414.Crossref, Google Scholar